Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
Rhea-AI Summary
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, has scheduled its fourth quarter and full year 2024 financial results release for Tuesday, February 25, 2025, before U.S. market opening.
The company will host a conference call and webcast at 8:00 a.m. ET on the same day, where management will discuss the results and provide updates on corporate developments. Participants can access the call through registration, and an audio webcast will be available through the company's Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FULC gained 1.86%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2024 financial results will be released on Tuesday, February 25, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When will Fulcrum Therapeutics (FULC) release its Q4 and full year 2024 earnings?
What time is FULC's Q4 2024 earnings call?
How can investors access FULC's Q4 2024 earnings call?
Will FULC's Q4 2024 earnings call webcast be available for replay?
